A major meta-analysis presented at ASN Kidney Week and published in two companion papers in JAMAprovides compelling evidence supporting the broad use of SGLT2 inhibitors across diverse chronic kidney disease (CKD) populations.
The analysis, conducted by the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ (SMART-C) Consortium led by The George Institute for Global Health, pooled data from over 70,000 participants across 10 randomized controlled trials. Findings address critical clinical questions about the effectiveness of these medications in advanced CKD, non-diabetic patients, and those with minimal proteinuria.
Key Findings on CKD Progression and Kidney Function
The first analysis demonstrated consistent benefits across all CKD stages:
- 38% reductionin risk of CKD progression compared to placebo
- 51% slowingof annual eGFR decline rate
- Benefits maintainedin Stage 4 CKD patients (eGFR <30 mL/min/1.73m²)
- Effectiveness confirmedin patients with minimal or no proteinuria (uACR ≤30 mg/g)
These findings are particularly significant as they include patient groups where SGLT2 inhibitor use has previously been uncertain or not specifically recommended.
Cardiovascular Benefits and Safety Profile
The second analysis revealed substantial cardiovascular protection across patient subgroups:
Heart failure hospitalization reduction: Nearly one-third in diabetic patients and one-quarter in non-diabetic patients
Consistent benefitsregardless of diabetes status or albuminuria level
Low riskof serious adverse events, with benefits substantially outweighing risks
The safety profile was favorable across all studied populations, supporting widespread use.
Clinical Implications and Global Health Impact
“These findings provide the strongest evidence to date supporting broad SGLT2 inhibitor use in CKD patients,” said Associate Professor Brendon Neuen, lead author and co-chair of SMART-C. “Our results support simplified treatment guidelines to encourage wider use of these medications.”
With CKD affecting approximately 850 million people globally and disproportionately impacting low- and middle-income countries, these findings have significant public health implications.
Future Directions and Implementation Challenges
As SGLT2 inhibitors become more affordable and available as generics in coming years, they present a unprecedented opportunity to transform care for millions worldwide.
The research highlights the need to address implementation barriers, particularly in regions with high CKD burden but limited access to these medications. Simplified treatment guidelines could help overcome clinical hesitancy in prescribing these agents to non-traditional patient groups.
Research Context and Consortium Leadership
The SMART-C Consortium, co-chaired by Associate Professor Brendon Neuen and Professor Hiddo Heerspink of The George Institute for Global Health, represents a collaborative international effort to synthesize evidence across major clinical trials.
This comprehensive analysis provides definitive evidence supporting SGLT2 inhibitor use across the spectrum of kidney function impairment and regardless of diabetes status, potentially changing clinical practice worldwide.
Related topics:
